podcasts Ratings /ratings/en/research-insights/podcasts/2019-08-01-the-sp-pharma-dose-episode-32-pfizer-finds-home-for-upjohn-though-lessened-diversity-results-in-lower-rating content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

In This List

The S&P Pharma Dose – Episode 32: Pfizer Finds Home For Upjohn, Though Lessened Diversity Results In Lower Rating

COMMENTS

COVID-19 Impact: Key Takeaways From Our Articles

COMMENTS

ESG Concerns In Oil And Gas Sectors Led To A Surge In Downgrade Pressure In January, Which Was Realized By Mid-February

COMMENTS

As European Hotels Grapple With Prolonged Restrictions, Are Operators And Landlords Sharing The Pain?

COMMENTS

Pharma Outlook: Eighth Straight Year Of Credit Deterioration In 2021

Listen: The S&P Pharma Dose – Episode 32: Pfizer Finds Home For Upjohn, Though Lessened Diversity Results In Lower Rating

The S&P Pharma Guy, Arthur Wong, shares S&P Global’s thoughts on Pfizer Inc.’s announcement it was spinning off Upjohn, home to legacy products Lipitor, Viagra, and Lyrica. Pfizer remains a pharma giant and leading player in the industry. However, the lessened diversity will result in a lower rating. 

Register with S&P Global Ratings

Register now to access exclusive content, events, tools, and more.

Go Back